Azole Antifungal Drugs: Classification, Structure, Mechanism of Action, Pharmacokinetics, Toxicity and Resistance

Table of Contents

• Introduction to Azoles
• Spectrum of activity of the Azoles
• Structure of the Azoles
• Classification of the Azoles
• Pharmacokinetics of Azoles
• Mode of Action of Azoles
• Toxicity of the Azoles
• Resistance factors of the Azoles
• Conclusion
• References

Introduction to Azoles

• Azoles are a major class of antifungal agents used to treat a broad range of fungal infections, including:
• Superficial mycoses, such as pityriasis versicolor and black and white piedra.
• Cutaneous mycoses, including tinea capitis and onychomycosis.
• Systemic mycoses, such as histoplasmosis and cryptococcosis.
• The primary antifungal action of azoles is the inhibition of ergosterol biosynthesis. Ergosterol is an essential sterol component of the fungal cell membrane and is required for maintaining membrane structure, stability, and function.
• Azoles primarily target the cytochrome P450-dependent enzyme 14-α-demethylase (CYP51), which is involved in the conversion of lanosterol, a precursor of ergosterol, into ergosterol.
• By inhibiting CYP51, azoles:
• Prevent the 14-α-demethylation of lanosterol.
• Reduce the synthesis of ergosterol.
• Cause the accumulation of abnormal sterols within the fungal cell membrane.
• Disrupt membrane structure and function, ultimately impairing fungal growth and viability.
• The disruption of membrane integrity can lead to fungal cell death. Depending on the specific azole, fungal species, and drug concentration, the overall effect may be fungistatic or fungicidal rather than universally causing apoptosis.
• Historically, benzimidazole was one of the earliest compounds containing a prominent azole structural entity. It was characterized by Woolley in 1944. However, the early research and potential significance of azole compounds received limited attention at the time.
• Subsequent research into azole-containing compounds led to the development of clinically important antifungal drugs and established the azole class as a major group of antifungal agents.

Spectrum of activity of the Azoles

• Azole antifungal agents have a broad spectrum of activity against a variety of yeasts, molds, and dermatophytes.
• Important fungi susceptible to different azole agents include:
• Blastomyces dermatitidis
• Histoplasma capsulatum
• Cryptococcus neoformans
• Aspergillus fumigatus
• Coccidioides immitis
• Candida spp., including:
• Candida albicans
• Candida tropicalis
• Candida glabrata
• Candida parapsilosis
• Candida krusei
• Candida lusitaniae
• Paracoccidioides brasiliensis
• Microsporum spp.
• Trichophyton spp.
• Epidermophyton floccosum
• The spectrum varies considerably among individual azoles. For example, some azoles have greater activity against dermatophytes and Candida species, whereas others have important activity against systemic dimorphic fungi and molds such as Aspergillus.
• Therefore, the choice of an azole depends on the causative fungal species, site and severity of infection, susceptibility profile, pharmacokinetic properties, and clinical characteristics of the patient.

Structure of the Azoles

• Azoles are five-membered heterocyclic aromatic compounds containing at least one nitrogen atom in the ring. The remaining heteroatom(s) may include nitrogen, oxygen, or sulfur, depending on the type of azole.
• Azole compounds are generally characterized by:
• Aromaticity, which provides electronic stability to the heterocyclic ring.
• Lipophilicity, which facilitates interaction with lipid-rich biological membranes and hydrophobic regions of target proteins.
• Weak basicity, due to the presence of nitrogen atoms with different electronic properties.
• Electron-rich heterocyclic rings, which contribute to their chemical reactivity and interactions with biological targets.
• Azoles exert their biological effects by interacting with specific enzymes or receptors. These interactions are primarily mediated through non-covalent forces, including:
• Hydrogen bonding
• Electrostatic interactions
• Van der Waals forces
• Hydrophobic interactions
• A major structural distinction among azoles is based on the number of nitrogen atoms present in the five-membered ring.

Imidazoles

• Imidazoles contain two nitrogen atoms within the five-membered heterocyclic ring.
• Their molecular formula is C₃H₄N₂.
• The two nitrogen atoms in imidazole are non-adjacent (separated by a carbon atom).
• Examples of clinically important imidazole antifungals include clotrimazole, miconazole, ketoconazole, and econazole.

Triazoles

• Triazoles contain three nitrogen atoms within the five-membered heterocyclic ring.
• Their molecular formula is C₂H₃N₃.
• The arrangement of the nitrogen atoms differs according to the triazole isomer, and they are not all necessarily adjacent to one another.
• The additional nitrogen atom alters the electronic properties, polarity, basicity, and pharmacological characteristics of triazoles compared with imidazoles.
• Clinically important triazole antifungals include fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole.

Classification of the Azoles

Azole antifungal agents are broadly classified into two major groups based on the number of nitrogen atoms present in their five-membered heterocyclic ring:

1. Imidazoles
2. Triazoles

1. Imidazoles

Imidazoles contain two nitrogen atoms in their five-membered heterocyclic ring. Important imidazole antifungal agents include:

• Clotrimazole
• Miconazole
• Econazole
• Ketoconazole
• Bifonazole
• Oxiconazole
• Chlormidazole

Chlormidazole

• Chlormidazole, also known as chlorobenzyl imidazole, was developed by Bayer AG in 1969 as a topical antifungal formulation.
• It has broad antimicrobial activity and has been used for oral thrush, vaginal candidiasis, and dermatophyte infections.
• It also exhibits activity against certain Gram-positive bacteria.

Miconazole

• Miconazole, a phenethyl imidazole derivative, was synthesized by Janssen Pharmaceutica in 1969.
• It became an important antifungal agent with activity against a range of fungi, including pathogenic yeasts, filamentous fungi such as Aspergillus spp., and dimorphic fungi.
• Miconazole also possesses activity against some Gram-positive bacteria.
• It is particularly effective for the treatment of superficial candidiasis.
• Historically, intravenous miconazole was investigated and used for systemic mycoses; however, its systemic use has largely been replaced by newer azole antifungals because of pharmacokinetic and safety limitations.

Econazole

• Econazole has a spectrum of activity broadly similar to that of miconazole and has a closely related chemical structure.
• It differs structurally from miconazole in the substitution pattern of its aromatic ring.
• Econazole is primarily available as a topical antifungal agent for the treatment of superficial fungal infections, including dermatophyte and Candida infections.
• It is not routinely used for systemic mycoses because of its pharmacokinetic properties and high protein binding.

Ketoconazole

• Ketoconazole was developed by Janssen Pharmaceutica in the 1970s and became the first widely used oral azole antifungal for systemic mycoses.
• Its introduction represented an important advance because it provided an orally administered option for treating systemic fungal infections.
• Although ketoconazole has broad antifungal activity, its use for systemic infections has declined substantially because of the risk of serious hepatotoxicity and adrenal effects.
• It is now primarily used in topical formulations for certain superficial fungal infections and seborrheic dermatitis.

2. Triazoles

Triazoles contain three nitrogen atoms in their five-membered heterocyclic ring and generally have broader systemic applications than many imidazoles.

They are commonly discussed in terms of first- and second-generation triazoles.

First-Generation Triazoles

The principal first-generation triazoles are:

1. Fluconazole
2. Itraconazole

Fluconazole

• Fluconazole was developed by Pfizer and became available in oral and intravenous (IV) formulations.
• It has excellent activity against many yeasts, particularly Candida spp., and is also active against Cryptococcus neoformans.
• Fluconazole has good penetration into several body fluids and tissues, including the central nervous system, making it clinically important in the treatment of cryptococcal meningitis.
• Structurally, fluconazole contains two 1,2,4-triazole rings and a difluorophenyl group.
• Its favorable pharmacokinetic properties and oral bioavailability have made it one of the most widely used systemic azole antifungals.

Itraconazole

• Itraconazole was developed by Janssen Pharmaceutica.
• It possesses a broad antifungal spectrum and is active against a variety of yeasts, dermatophytes, and dimorphic fungi.
• It has important activity against certain Aspergillus spp. and is also used against infections caused by Sporothrix schenckii.
• Itraconazole is available in oral formulations and is used for several superficial, subcutaneous, and systemic fungal infections.

Second-Generation Triazoles

Second-generation triazoles include:

• Voriconazole
• Posaconazole
• Ravuconazole

These agents were developed to provide broader or enhanced antifungal activity and improved pharmacological properties compared with earlier triazoles.

• Voriconazole has potent activity against Aspergillus spp. and is an important treatment option for invasive aspergillosis.
• Posaconazole has a broad spectrum that includes many yeasts and molds and is particularly important for the prevention and treatment of invasive fungal infections in high-risk patients.
• Ravuconazole is a newer triazole with broad antifungal activity that has been investigated for several fungal infections.

Pharmacokinetics of Azoles

• The pharmacokinetic properties of azole antifungals vary considerably among individual drugs. Differences in lipophilicity, aqueous solubility, gastric absorption, protein binding, metabolism, tissue penetration, and elimination influence their clinical use.
• Many azoles are lipophilic weak bases. Their physicochemical properties influence their dissolution, absorption, distribution, and oral bioavailability.
• Some highly lipophilic azoles have pH-dependent dissolution. For example, ketoconazole and itraconazole require an acidic gastric environment for optimal dissolution and absorption.
• The lipophilic nature of many azoles facilitates their ability to cross biological membranes and distribute into tissues. However, tissue penetration varies substantially among individual azoles.

Ketoconazole

• Administration: Primarily administered orally for systemic exposure; topical formulations are also available.
• Absorption: Oral absorption is strongly influenced by gastric acidity. An acidic gastric environment promotes dissolution, whereas increased gastric pH can substantially reduce absorption.
• Food: Food may influence ketoconazole absorption, and administration recommendations depend on the formulation. For systemic ketoconazole tablets, an acidic environment is particularly important for adequate absorption.
• Distribution: Ketoconazole has poor penetration across the blood–brain barrier, resulting in inadequate concentrations in the cerebrospinal fluid for effective treatment of fungal meningitis.
• Metabolism: It undergoes extensive hepatic metabolism, primarily involving CYP3A4, producing multiple metabolites.
• Elimination: Drug and metabolites are eliminated predominantly through the biliary/fecal route, with only a small proportion eliminated unchanged in urine.

Fluconazole

• Administration: Fluconazole can be administered orally or intravenously (IV).
• Solubility: Compared with many other azoles, fluconazole is relatively water-soluble, contributing to its favorable pharmacokinetic profile.
• Protein binding: It exhibits low plasma protein binding, with most of the drug remaining unbound in circulation.
• Bioavailability: Oral fluconazole has high bioavailability (approximately 90%), and oral exposure is comparable to intravenous administration.
• Food and gastric pH: Its absorption is not significantly affected by food or gastric acidity, making its oral administration relatively predictable.
• Distribution: Fluconazole distributes widely throughout body tissues and fluids and penetrates well into the cerebrospinal fluid (CSF). This property makes it particularly useful in the treatment of susceptible fungal infections involving the central nervous system, including cryptococcal meningitis.
• Metabolism: Unlike many other azoles, fluconazole undergoes limited hepatic metabolism.
• Elimination: The drug is eliminated primarily through the kidneys, with a large proportion excreted in the urine unchanged.

Itraconazole

• Administration: Itraconazole is primarily administered orally. An intravenous formulation has also been used in some settings.
• Intravenous formulation: The IV formulation uses hydroxypropyl-β-cyclodextrin as a solubilizing agent to improve the aqueous solubility of the highly lipophilic drug. This excipient can accumulate in patients with impaired renal function and has been associated with renal toxicity, limiting its use in certain patients.
• Absorption: Oral absorption is influenced by food and gastric acidity, although the effect depends on the formulation. The oral solution and capsules have different absorption characteristics.
• Metabolism: Itraconazole undergoes extensive hepatic metabolism, primarily through CYP3A4, producing several metabolites. One of its major active metabolites is hydroxy-itraconazole, which contributes substantially to antifungal activity.
• Elimination: Itraconazole and its metabolites are eliminated through both feces and urine, predominantly as metabolites. Approximately 3–18% of the administered dose is excreted unchanged in feces, while urinary excretion accounts for a smaller proportion of unchanged drug; the commonly cited percentages therefore depend on whether the parent drug or total metabolites are being measured.
• Because itraconazole is extensively metabolized and highly lipophilic, its pharmacokinetic profile differs markedly from that of fluconazole.

Mode of Action of Azoles

• The primary mechanism of action of azole antifungals is the inhibition of ergosterol biosynthesis, an essential pathway for maintaining the structure and function of the fungal cell membrane.
• Azoles target the fungal cytochrome P450-dependent enzyme sterol 14α-demethylase (CYP51), which catalyzes the removal of the 14α-methyl group from lanosterol during ergosterol biosynthesis.
• The nitrogen atom of the azole ring coordinates with the heme iron (Fe³⁺) present in the active site of CYP51. This interaction inhibits the enzyme and prevents the normal demethylation of lanosterol.
• The resulting inhibition causes:
• Decreased ergosterol synthesis
• Accumulation of abnormal sterol intermediates
• Alteration of fungal membrane composition
• Loss of membrane integrity and function
• Ultimately, inhibition of fungal growth and viability
• Because ergosterol is essential for maintaining fungal membrane structure, its depletion disrupts membrane-associated processes, including membrane fluidity, permeability, and the activity of membrane-bound proteins.

Secondary Effects

• In addition to disrupting sterol biosynthesis, azoles may affect oxidative and peroxidative enzyme systems within fungal cells.
• These effects can contribute to the accumulation of reactive oxygen species (ROS), including hydrogen peroxide (H₂O₂), producing additional oxidative stress and cellular damage.
• The contribution of oxidative stress to azole-mediated antifungal activity can vary depending on the azole compound and fungal species.

Mechanism of Triazoles

• Triazoles share the fundamental mechanism of action of imidazoles: both inhibit CYP51/sterol 14α-demethylase by coordinating an azole nitrogen with the heme iron of the enzyme.
• However, individual triazoles can differ in their binding affinity, selectivity, spectrum of activity, and effects on other sterol-biosynthetic enzymes.
• In some fungi, triazole treatment can also interfere with downstream sterol pathways and lead to alterations in sterol intermediates such as obtusifoliol.

Effects on Sterol Biosynthesis in Cryptococcus neoformans

• In Cryptococcus neoformans, azoles such as itraconazole and fluconazole can affect the sterol biosynthetic pathway beyond CYP51 inhibition.
• These drugs can suppress the activity of 3-ketoreductase, an enzyme involved in the conversion of 3-ketosteroid obtusifolione to obtusifoliol.
• Inhibition of this pathway contributes to the accumulation of sterol intermediates and disruption of normal fungal sterol metabolism, further compromising fungal cell membrane function.
• Overall, the antifungal activity of azoles results primarily from CYP51 inhibition and disruption of ergosterol/sterol biosynthesis, with additional metabolic and cellular effects contributing to fungal growth inhibition.

Toxicity of the Azoles

• The adverse effects of azole antifungals vary depending on the specific drug, dose, duration of treatment, route of administration, and patient characteristics.
• Common adverse effects associated with systemic azole therapy include:
• Gastrointestinal disturbances, such as nausea, vomiting, abdominal discomfort, and diarrhea.
• Hepatotoxicity, ranging from elevated liver enzymes to hepatitis and, rarely, severe hepatic injury.
• Dizziness and headache.
• Skin rashes and hypersensitivity reactions.
• Electrolyte abnormalities, including hypokalemia with certain azole agents.
• Some azoles may also produce neurological, cardiovascular, or endocrine adverse effects depending on the drug.
• Ketoconazole has an additional important endocrine toxicity because it inhibits several cytochrome P450-dependent enzymes involved in steroid hormone synthesis.
• By inhibiting corticosteroid synthesis, particularly cortisol production, ketoconazole can cause adrenocortical insufficiency (adrenal insufficiency).
• Ketoconazole can also inhibit androgen synthesis, potentially resulting in reduced testosterone production and other endocrine effects.
• Due to its potential for serious hepatotoxicity and adrenal suppression, systemic oral ketoconazole is generally avoided when safer alternative antifungal agents are available.

Resistance factors of the Azoles

• Azole resistance, particularly resistance to fluconazole, is an important clinical problem in Candida albicans. Resistance can develop through several mechanisms, often involving alterations in drug efflux, drug targets, and sterol biosynthesis.
• Increased drug efflux: One of the major mechanisms of azole resistance is the increased removal of the drug from the fungal cell. Two major families of membrane transporters are involved:
• ATP-binding cassette (ABC) transporters: CaCdr1p and CaCdr2p belong to the pleiotropic drug resistance (PDR) subfamily of ABC transporters. Their increased expression enhances the active efflux of azoles from the fungal cell, reducing intracellular drug concentrations.
• Major facilitator superfamily (MFS) transporters: The MFS family includes transporter groups such as DHA1 and DHA2 that can contribute to azole resistance. In C. albicans, Mdr1p and Flu1p are associated with azole efflux and can reduce intracellular drug accumulation.
• Overexpression of CDR1 and CDR2 can therefore significantly increase azole efflux and contribute to resistance.
• Increased drug target expression: Azoles primarily inhibit Erg11p (sterol 14α-demethylase/CYP51). Overexpression of the ERG11 gene increases the amount of target enzyme present in the fungal cell, meaning that higher concentrations of the drug may be required to achieve effective inhibition.
• The transcription factor Upc2p, encoded by the UPC2 gene, regulates genes involved in ergosterol biosynthesis, including ERG11.
• Gain-of-function mutations in UPC2 can increase Upc2p activity, resulting in increased expression of ERG11 and other sterol-biosynthesis genes.
• Consequently, greater amounts of Erg11p may reduce the effectiveness of azoles at concentrations that would normally inhibit fungal growth.
• Point mutations in ERG11: Mutations in the ERG11 gene can alter the structure of Erg11p and reduce the binding affinity of azoles for the enzyme's active site and heme region.
• In C. albicans, substitutions such as Y132F and K143R have been associated with clinically important fluconazole resistance.
• These amino acid substitutions can reduce azole–Erg11p interactions, allowing ergosterol biosynthesis to continue despite drug exposure.
• Alterations in ergosterol biosynthesis: Additional resistance mechanisms can involve changes in the expression or activity of other enzymes in the ergosterol biosynthetic pathway. These changes may allow fungal cells to maintain membrane sterol homeostasis despite inhibition of Erg11p.
• Overall, azole resistance can result from a combination of mechanisms, particularly increased drug efflux, overexpression or structural alteration of the drug target, and remodeling of the ergosterol biosynthetic pathway. These mechanisms can reduce intracellular drug concentrations or decrease the susceptibility of the target enzyme, ultimately lowering the antifungal efficacy of azole therapy.

Conclusion

• The increasing incidence of mycotic infections is associated with several clinical factors that compromise the normal defenses of the host. The use of broad-spectrum antibiotics can disrupt the normal bacterial microbiota, reducing bacterial competition and allowing opportunistic fungi to colonize and proliferate.
• An increasing population of immunocompromised patients is also highly susceptible to opportunistic fungal infections. Similarly, invasive surgical procedures and accidental trauma can damage anatomical barriers, which form an important component of the body's innate defense system, providing fungi with opportunities to enter normally protected tissues.
• The use of immunosuppressive therapies, including myeloablative and cytotoxic treatments, can further weaken host immune defenses and increase susceptibility to invasive mycoses.
• Effective management of fungal infections requires consideration of the pharmacokinetic properties, tissue distribution, drug interactions, and safety profiles of individual azole antifungals.
• Appropriate selection and optimization of antifungal therapy, including combination therapy when clinically justified, may improve treatment outcomes and help prevent or manage serious mycotic infections.
• Overall, understanding the mechanisms of action, pharmacokinetics, toxicity, and resistance mechanisms of azoles is essential for their rational use in the treatment and prophylaxis of prevalent fungal infections.

References

• Bellmann, R., & Smuszkiewicz, P. (2017). Pharmacokinetics of antifungal drugs: Practical implications for optimized treatment of patients. Infection, 45(6), 737–779. https://doi.org/10.1007/s15010-017-1042-z
• Denyer, S. P., Hodges, N. A., & Gorman, S. P. (2004). Hugo and Russell’s pharmaceutical microbiology (7th ed., p. 51). Blackwell Science.
• El-Garhy, O. H. (2015). An overview of the azoles of interest. International Journal of Current Pharmaceutical Research, 7(1), 1–6.
• Emami, L., Faghih, Z., Ataollahi, E., Sadeghian, S., Rezaei, Z., & Khabnadideh, S. (2022). Azole derivatives: Recent advances as potent antibacterial and antifungal agents. Current Medicinal Chemistry, 30(2), 220–249. https://doi.org/10.2174/0929867329666220407094430
• Fromtling, R. A. (1988). Overview of medically important antifungal azole derivatives. Clinical Microbiology Reviews, 1(2).
• Li, Y., Hind, C., Furner-Pardoe, J., Sutton, J. M., & Rahman, K. M. (2025). Understanding the mechanism of resistance to azole antifungals in Candida spp. JAC-Antimicrobial Resistance, 7(3). https://doi.org/10.1093/jacamr/dlaf106
• Saag, M. S., & Dismukes, W. E. (1988). Azole antifungal agents: Emphasis on new triazoles. Antimicrobial Agents and Chemotherapy, 32(1), 1–8.